Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
GOVXW logo GOVXW
Upturn stock rating
GOVXW logo

GeoVax Labs Inc (GOVXW)

Upturn stock rating
$0.01
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

09/24/2025: GOVXW (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Analysis of Past Performance

Type Stock
Historic Profit -21.43%
Avg. Invested days 33
Today’s Advisory PASS
Upturn Star Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulation Last Close 09/24/2025

Key Highlights

Company Size ETF
Market Capitalization 0 USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) -
Beta 3.44
52 Weeks Range 0.01 - 0.65
Updated Date 06/28/2025
52 Weeks Range 0.01 - 0.65
Updated Date 06/28/2025
Dividends yield (FY) -
Basic EPS (TTM) -

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -330.18%

Management Effectiveness

Return on Assets (TTM) -915.19%
Return on Equity (TTM) -78814.56%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding -
Shares Floating 13761977
Shares Outstanding -
Shares Floating 13761977
Percent Insiders -
Percent Institutions -

ai summary icon Upturn AI SWOT

GeoVax Labs Inc

stock logo

Company Overview

overview logo History and Background

GeoVax Labs, Inc. was founded in 2001. The company focuses on developing human vaccines, utilizing a Modified Vaccinia Ankara-Virus Like Particle (MVA-VLP) platform. Its initial focus was on HIV vaccines, evolving to include vaccines for other infectious diseases and cancer.

business area logo Core Business Areas

  • Vaccine Development: GeoVax develops and tests vaccines based on its MVA-VLP platform, targeting infectious diseases (HIV, Zika, Lassa fever) and cancers. These vaccines are designed to stimulate both antibody and T-cell responses.
  • Licensing and Partnerships: The company licenses its MVA-VLP technology and collaborates with other organizations, including government agencies (e.g., NIH) and pharmaceutical companies, to advance vaccine development.
  • Research and Development: GeoVax focuses on ongoing R&D to improve its vaccine platform and expand its pipeline of vaccine candidates.

leadership logo Leadership and Structure

David Dodd is the Chairman, President and CEO. The company has a Board of Directors and a management team overseeing research, clinical trials, and corporate operations.

Top Products and Market Share

overview logo Key Offerings

  • HIV Vaccine Candidates: GeoVax's primary focus has been on HIV vaccine candidates. While no product has yet achieved market approval, the company continues to conduct clinical trials. Market share is currently zero as there is no approved vaccine for HIV. Competitors include Moderna (MRNA) and other companies developing preventative and therapeutic HIV vaccines.
  • Zika Vaccine Candidates: GeoVax has developed Zika vaccine candidates, seeking to address the unmet need for protection against the Zika virus. Market share is currently zero as there is no approved vaccine for Zika. Competitors include Inovio Pharmaceuticals (INO) and Takeda Pharmaceutical Company Limited (TAK).
  • Lassa Fever Vaccine Candidates: GeoVax develops Lassa Fever vaccine candidates. Market share is currently zero as there is no approved vaccine for Lassa Fever. Competitors include IAVI and Emergent BioSolutions (EBS).

Market Dynamics

industry overview logo Industry Overview

The vaccine industry is driven by global health needs, technological advancements (e.g., mRNA vaccines), and regulatory approvals. It's a competitive landscape with established players and emerging biotech firms.

Positioning

GeoVax is a smaller player focused on its MVA-VLP platform. Its competitive advantage lies in its proprietary technology, designed to elicit strong immune responses. However, its market position is challenged by larger companies with more resources and established pipelines.

Total Addressable Market (TAM)

The TAM for vaccines is estimated to be over $50 billion, depending on the year and specific disease areas. GeoVax is positioned to capture a portion of this through licensing, partnerships, and eventual commercialization of its vaccine candidates.

Upturn SWOT Analysis

Strengths

  • Proprietary MVA-VLP vaccine platform
  • Potential for strong immune responses
  • Partnerships with government agencies and research institutions
  • Experienced leadership team

Weaknesses

  • Limited financial resources
  • Dependence on grant funding and partnerships
  • No currently approved products
  • Smaller scale compared to larger pharmaceutical companies

Opportunities

  • Potential for licensing agreements
  • Advancements in vaccine technology
  • Government funding for vaccine development
  • Growing demand for vaccines against emerging infectious diseases

Threats

  • Competition from larger pharmaceutical companies
  • Regulatory hurdles
  • Clinical trial failures
  • Intellectual property challenges

Competitors and Market Share

competitor logo Key Competitors

  • MRNA
  • INO
  • TAK
  • EBS

Competitive Landscape

GeoVax faces intense competition from larger, better-funded pharmaceutical companies. Its competitive advantage hinges on the efficacy and cost-effectiveness of its MVA-VLP platform.

Growth Trajectory and Initiatives

Historical Growth: Historical growth has been limited, driven primarily by grant funding and research advancements.

Future Projections: Future growth is dependent on successful clinical trials, regulatory approvals, and licensing agreements. Analyst estimates vary widely given the inherent uncertainty of biotech development.

Recent Initiatives: Recent initiatives include focusing on COVID-19 vaccine development, expanding its cancer vaccine program, and securing additional grant funding.

Summary

GeoVax Labs is a biotech company with a promising MVA-VLP vaccine platform, but faces significant challenges. Its success hinges on positive clinical trial results and securing funding. Competition from larger pharmaceutical companies and regulatory hurdles pose substantial risks. The company needs to achieve key milestones to prove the efficacy of its platform.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company website
  • SEC filings
  • Press releases
  • Market research reports
  • Analyst reports

Disclaimers:

This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual risk tolerance and thorough research. Market share estimates are approximate and based on available data.

Upturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About GeoVax Labs Inc

Exchange NASDAQ
Headquaters Smyrna, GA, United States
IPO Launch date 2020-09-25
Chairman, President & CEO Mr. David Alan Dodd
Sector Healthcare
Industry Biotechnology
Full time employees 17
Full time employees 17

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. The company is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. It also developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, the company offers GEO-MVA-MUC1, a vaccine candidate, which is in preclinical trial for the treatment of solid tumor cancers; GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-EMO1-Z, which is in preclinical trial for the treatment of Ebola Zaire; GEO-EMO1-S, which is in preclinical trial for the treatment of Ebola Sudan; GEO-MM01 treatment for marburg; and GEO-MVA for the treatment of Mpox and small pox. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.